Biotech CRO

Yes. We specialize in early-phase and first-in-human trials, helping biotechs build data infrastructure, define standards, and make smart upfront decisions that prevent delays and reduce risk later in the development process.

Bioforum has supported more than 700 studies since 2008 for over 150 global customers, across all phases: approximately 25 percent Phase I, 29 percent Phase II, 38 percent Phase III and 9 percent post-marketing. The therapeutic mix spans oncology as the largest single area at 23 percent, followed by neurology, psychiatry, cardiology, orthopedics, dermatology, gastroenterology, ophthalmology, gynecology, immunology, endocrinology, rheumatology, urology and respiratory.

Yes. Bioforum operates six subsidiaries across ten countries, supporting sponsors and sites worldwide with coverage across all time zones. Sponsors range from emerging biotechs and medical device companies to big and mid-size pharma, academic and non-profit research institutes, and other CROs.

Preparation integrates data cleaning, reconciliation, coding, protocol deviation review, SAP finalization, programming, quality control and communications. Bioforum identifies decision points, critical data sources, review owners and contingencies for late data, and uses mock outputs and dry runs to surface specification gaps before the final cut, supporting timely interpretation without compromising validation or traceability.